(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Desired Travel Objections Worldwide: Where to Go Straightaway - 2Vote in favor of the pasta that makes good dieting pleasant!
- 3Which European palace do you fantasy about visiting? Vote!
- 4Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- 5Artemis II astronauts are more than halfway to the moon as they seek to break Apollo 13's record
- Aspect Biosystems receives funding for cellular medicine project
- Vote in favor of the wide open action that revives your brain and soul!
- The Manual for Electric Vehicles that will be hot dealers in 2023
- Anthony Joshua's driver charged over Nigeria crash that killed two
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- Immortal Style: Closet Staples for Each Age
- Tremendous Spelunking: Cool Caverns All over the Planet
- Poland identifies two Ukrainian suspects in railway sabotage blast
